Eli Lilly announced that all approved doses of Zepbound (tirzepatide), including the highest strengths—12.5 mg and 15 mg—will be available in single-dose vials for $499/month or less through LillyDirect's Self Pay Pharmacy Solutions starting August 2025. Prescriptions for these doses can be written beginning July 7.

This move makes the full range of Zepbound strengths accessible to eligible adults with obesity regardless of insurance status, further advancing Lilly’s efforts to reduce barriers to care. Zepbound is the only FDA-approved dual GIP and GLP-1 receptor agonist indicated for chronic weight management and, more recently, for obesity-related obstructive sleep apnea.

Dr. Lydia Alexander, Immediate Past President of the Obesity Medicine Association, commented in a LinkedIn post that the update is “a welcome move” in addressing the affordability and stigma often tied to obesity care, noting that while the cost may still be out of reach for some, it represents progress toward more equitable treatment access.

Lilly’s self-pay pricing follows similar steps taken by Novo Nordisk for Wegovy and reflects growing industry pressure to make weight-loss medications more attainable in the absence of broad insurance coverage.

For more information, please visit zepbound.lilly.com.